Background: Recent meta-analyses suggest that higher removal of beta-2 microglobulin (β2M) with either high-flux (HFD) dialysis or hemodiafiltration (HDF) may be associated with decreased total and cardiovascular mortality in dialysis patients. However, there are limited data about the performance of high flux dialyzers and/or convective therapies in removing β2M. Methods: This is a random effects meta-analysis and meta-regression of data extracted from randomized controlled trials and observational studies in hemodialysis, hemofiltration and HDF regarding the efficiency of high flux dialyzers to remove β2M. Studies were searched using ProQuest in SCOPUS, EMBASE and MEDLINE. Results: We included 69 studies from 1 January 2001 to 12 June 2017 on 1879 patients with 6771 available measurements. Average β2M clearance was 48.75 mL/min [95% confidence interval (CI) 42.50-55.21] for conventional HF dialysis, and 87.06 mL/min (95% CI 75.08-99.03) for convective therapies (hemofiltration and HDF) with substantial heterogeneity among studies [P (Q) ≤ 0.001]. In multivariable meta-regression analyses, we found significantly higher β2M clearance for polyarylethersulfone dialyzers when used for HFD and polysulfone membranes in convective therapies. However, the mass of β2M removed into the dialysate did not depend on membrane material. Adjusted dialysate-side (-22.279, 95% CI -9.8 to -34.757, P < 0.001) β2M clearances were significantly lower than whole blood clearances, suggesting that adsorption contributes substantially to β2M removal. Higher Kuf, blood flow and substitution fluid rates but not dialysate flow rates were associated with statistically significant and clinically meaningful elevation in β2M clearance from the body independent of the dialysis modality. Conclusions: Membrane composition and characteristics, modality (convective versus diffusive), blood flow rates and substitution fluid rates in HDF play a significant role in the efficient removal of β2M from the body in both diffusive and convective dialysis.
Background: Recent meta-analyses suggest that higher removal of beta-2 microglobulin (β2M) with either high-flux (HFD) dialysis or hemodiafiltration (HDF) may be associated with decreased total and cardiovascular mortality in dialysis patients. However, there are limited data about the performance of high flux dialyzers and/or convective therapies in removing β2M. Methods: This is a random effects meta-analysis and meta-regression of data extracted from randomized controlled trials and observational studies in hemodialysis, hemofiltration and HDF regarding the efficiency of high flux dialyzers to remove β2M. Studies were searched using ProQuest in SCOPUS, EMBASE and MEDLINE. Results: We included 69 studies from 1 January 2001 to 12 June 2017 on 1879 patients with 6771 available measurements. Average β2M clearance was 48.75 mL/min [95% confidence interval (CI) 42.50-55.21] for conventional HF dialysis, and 87.06 mL/min (95% CI 75.08-99.03) for convective therapies (hemofiltration and HDF) with substantial heterogeneity among studies [P (Q) ≤ 0.001]. In multivariable meta-regression analyses, we found significantly higher β2M clearance for polyarylethersulfone dialyzers when used for HFD and polysulfone membranes in convective therapies. However, the mass of β2M removed into the dialysate did not depend on membrane material. Adjusted dialysate-side (-22.279, 95% CI -9.8 to -34.757, P < 0.001) β2M clearances were significantly lower than whole blood clearances, suggesting that adsorption contributes substantially to β2M removal. Higher Kuf, blood flow and substitution fluid rates but not dialysate flow rates were associated with statistically significant and clinically meaningful elevation in β2M clearance from the body independent of the dialysis modality. Conclusions: Membrane composition and characteristics, modality (convective versus diffusive), blood flow rates and substitution fluid rates in HDF play a significant role in the efficient removal of β2M from the body in both diffusive and convective dialysis.
Authors: Damien Ashby; Natalie Borman; James Burton; Richard Corbett; Andrew Davenport; Ken Farrington; Katey Flowers; James Fotheringham; R N Andrea Fox; Gail Franklin; Claire Gardiner; R N Martin Gerrish; Sharlene Greenwood; Daljit Hothi; Abdul Khares; Pelagia Koufaki; Jeremy Levy; Elizabeth Lindley; Jamie Macdonald; Bruno Mafrici; Andrew Mooney; James Tattersall; Kay Tyerman; Enric Villar; Martin Wilkie Journal: BMC Nephrol Date: 2019-10-17 Impact factor: 2.388
Authors: Maaike K van Gelder; Igor R Middel; Robin W M Vernooij; Michiel L Bots; Marianne C Verhaar; Rosalinde Masereeuw; Muriel P Grooteman; Menso J Nubé; M A van den Dorpel; Peter J Blankestijn; Maarten B Rookmaaker; Karin G F Gerritsen Journal: Toxins (Basel) Date: 2020-04-07 Impact factor: 4.546
Authors: Luciano A Pedrini; Adam M Zawada; Anke C Winter; Jenny Pham; Gudrun Klein; Melanie Wolf; Astrid Feuersenger; Pio Ruggiero; Annalisa Feliciani; Carlo Barbieri; Adelheid Gauly; Bernard Canaud; Stefano Stuard Journal: PLoS One Date: 2019-02-22 Impact factor: 3.240
Authors: Eiichiro Kanda; Daniel Muenz; Brian Bieber; Aleix Cases; Francesco Locatelli; Friedrich K Port; Roberto Pecoits-Filho; Bruce M Robinson; Jeffrey Perl Journal: Clin Kidney J Date: 2020-10-27
Authors: Tadashi Tomo; Maria Larkina; Ayumi Shintani; Tomonari Ogawa; Bruce M Robinson; Brian Bieber; Lisa Henn; Ronald L Pisoni Journal: BMC Nephrol Date: 2021-10-14 Impact factor: 2.388